Gabapentin Tablet
Product Images NDC 68071-2206

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2206). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2206 1)

This is a description for a medication called Gabapentin in 800mg doses. It is a prescription medication that has a lot number of 000000 and is also identified by the NDC numbers 68071-2206-1 and 68071-2206-01. The manufacturer's NDC number is 50228-178-01, and the medication comes in a bottle of 100 tablets. The medication has an expiration date of 00-00 and a serial number of 00000000002. It is to be stored at a controlled temperature of 59-86°F and should be kept out of children's reach. If you experience any side effects, call your doctor immediately, and you may also report them to the FDA.*

FDA Label Image

Figure 1 (Image 01)

This appears to be a chart or table, and without further context, it is not clear what it represents. Therefore, a useful description cannot be generated.*

FDA Label Image

Figure 2 (Image 02)

This is a graph showing the mean pain scores of individuals over a 4-week fixed dose period with either a placebo or Gabapentin (at doses of 1800 or 2400 mg/day). The x-axis represents the weeks of the study, while the y-axis shows the pain scores. The data appears to indicate that higher doses of Gabapentin correspond to lower mean pain scores.*

FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Cockcroft And Gault Equation (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.